Mon, Sep 16, 2024
Axis Direct has given a 'buy' rating on Balrampur Chini. The brokerage has given a target of Rs 638 and a stop loss of Rs 560. This means the stock has an upside of 12 per cent from its last closing price.
More >
Mon, Jul 29, 2024
Strides Pharma Science's revenue stood at Rs 1,087 crore in the period under review compared to Rs 932 crore in the year-ago quarter, the pharma company said.
Wed, May 22, 2024
Total expenses in the fourth quarter were higher at Rs 984.21 crore as compared to Rs 972.26 crore.The board has recommended a final dividend of Rs 2.50 per equity share of Rs 10 each for the financial year ended March 31, 2024, the filing said.
Tue, Nov 21, 2023
Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic medication for seizures.
Mon, Oct 30, 2023
Total income, however, rose to Rs 1,035 crore in the second quarter as compared with Rs 920 crore in the year-ago period, Strides Pharma said in a regulatory filing.
Wed, Oct 04, 2023
Strides Pharma Science said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Mon, Sep 25, 2023
The company's board has approved a scheme of arrangement amongst Strides Pharma Science, Steriscience Specialties and Stelis Biopharma, the drug firm said in a regulatory filing.
Strides Pharma news: Strides Pharma Science announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, received USFDA (United States Food and Drug Administration) approval for Icosapent Ethyl Capsules 0.5 gram and 1 gram.
Fri, Sep 15, 2023
Strides Pharma Science share price NSE: Pharmaceutical company Strides Pharma Science shares rallied on Friday for the third straight day and zoomed nearly 12 per cent to clock a fresh 52-week high of Rs 522.75
Wed, Aug 30, 2023
The approval granted by the US Food & Drug Administration (USFDA) is for Mycophenolate Mofetil for oral suspension of strength 200 mg/ml, Strides Pharma Science said in a regulatory filing.
Tue, Jan 24, 2023
Q3 Results 2023: Listed companies on the BSE and NSE continued to announce their quarterly earnings on Tuesday. Some of the companies which declared their October-December results included Uco Bank, Macrotech Developers and Strides Pharma.
Wed, Aug 10, 2022
Consequently, the Nifty50 on Monday ended around the day’s high to close at 17,525 levels. The broader indices also closed with modest gains.
Wed, Jun 29, 2022
Extending gains for the fourth session, the Indian market ended higher by around one per cent aided by positive global cues.
Wed, Dec 29, 2021
The rise of the Covid-19 variant Omicron has once again brought pharma shares in focus.
Tue, Jul 13, 2021
The shares of Strides Pharma and Astral Limited each jumped around 5 per cent to Rs 809.15 and Rs 2134 per share on the BSE intraday trade today as both the stocks made entry into Futures & Options (F&O) space for the August series, as per the exchanges.
Thu, Apr 22, 2021
Zee Business Managing Editor Anil Singhvi said that the reason for taking up this stock today is because investors have not considered whether it may benefit from Covid pandemic. In fact, notably, this stock has not moved the way other pharma companies have moved. Today's SIP stock is Strides Pharma
Fri, Apr 16, 2021
In a chat with Zee Business Managing Editor Anil Singhvi today, market expert Jay Thakkar recommended his top three mid-cap stock picks for investors to buy, which he said have great potential to earn bumper returns. These stocks were recommended with long-term, positional medium-term, and short-term views. Know why this analyst thinks these stocks hold promise!
Mon, Nov 23, 2020
Players who are late to the chase run the risk of launching when the market is saturated, resources are distributed, and the pandemic is almost over. All want the pandemic to end soon, but this may inversely correlate with research intensity. The smart companies took advantage of COVID-19 to improve efficiency of their research (Junshi) and manufacturing (Strides Pharma) and strengthen their reputation (WuxiBio) through good execution.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
